Effect of timing of surgery on survival after preoperative hyperfractionated accelerated radiotherapy (HART) for locally advanced rectal cancer (LARC): Is it a matter of days?

被引:19
|
作者
Coucke, Philippe A. [1 ]
Notter, Markus
Matter, Maurice
Fasolini, Fabrizio
Calmes, Jean-Marie
Schlumpf, Rolph
Schwegler, Norbert
Stamm, Bernhard
Do, Hu Phuoc
Bouzourene, Hanifa
机构
[1] CHU Liege, Dept Radiat Oncol, Liege, Belgium
[2] CHU Vaudois, Dept Human Pathol, Lausanne, Switzerland
[3] Kantonspital Aarau, Aarau, Switzerland
[4] CHU Vaudois, Dept Surg, Lausanne, Switzerland
[5] CHU Vaudois, Dept Radiat Oncol, Lausanne, Switzerland
关键词
D O I
10.1080/02841860600891317
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We intend to analyse retrospectively whether the time interval ("gap duration'' = GD) between preoperative radiotherapy and surgery in locally advanced rectal cancer ( LARC) has an impact on overall survival ( OS), cancer specific survival (CSS), disease free survival (DFS) and local control (LC). Two hundred seventy nine patients with LARC were entered in Trial 93-01 (hyperfractionated accelerated radiotherapy 41.6 Gy/26 Fx BID) shortly followed by surgery. From these 250 patients are fully assessable. The median GD of 5 days was used as a discriminator. The median follow-up for all patients was 39 months. GD > 5 days was a significant discriminator for actuarial 5-years OS (69% vs 47%, p = 0.002), CSS ( 82% vs 57%, p = 0.0007), DFS (62% vs 41%, p = 0.0003) but not for LC ( 93% vs 90%, p = non-significant). In multivariate analysis, the following factors independently predict outcome; for OS: age, GD, circumferential margin ( CM) and nodal stage (ypN); for CSS: GD, ypN and vascular invasion (VI); for DFS: CEA, distance to anal verge, GD, ypN and VI; for LC: CM only. Gap duration predicts survival outcome but not local control. The patients submitted to surgery after a median delay of more than 5 days had a significantly better outcome.
引用
收藏
页码:1086 / 1093
页数:8
相关论文
共 50 条
  • [21] Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy (HART) in resectable distal rectal cancer
    Ceelen, W
    Zwaenepoel, O
    Gillardin, JM
    Boterberg, T
    Van Damme, N
    Pattyn, P
    Peeters, M
    ANNALS OF ONCOLOGY, 2006, 17
  • [22] Preoperative chemotherapy and radiotherapy for locally advanced rectal cancer
    Chao, M
    Gibbs, P
    Tjandra, J
    Cullinan, M
    McLaughlin, S
    Faragher, I
    Skinner, I
    Jones, I
    ANZ JOURNAL OF SURGERY, 2005, 75 (05) : 286 - 291
  • [23] Preoperative hyperfractionated accelerated radiotherapy (HART) plus concomitant infusional 5-fluorouracil in stage T3 and locally advanced primary rectal cancer: Study of a single institution.
    Cordio, S
    Marletta, F
    Foresta, G
    Franco, S
    Greco, P
    Giuffrida, D
    Manusia, M
    Taffuri, G
    Giannone, G
    Failla, G
    ANNALS OF ONCOLOGY, 2000, 11 : 54 - 55
  • [24] Preoperative capecitabine, oxaliplatin and high-dose pelvic conformal radiotherapy in locally advanced rectal cancer (LARC).
    Tucci, E
    Algeri, R
    Giulianotti, PC
    Pecci, AP
    Schiaroli, G
    Sbrana, F
    Perillo, F
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 281S - 281S
  • [25] Impact of colloid response on survival after preoperative radiotherapy in locally advanced rectal carcinoma
    Rullier, A
    Laurent, C
    Vendrely, V
    Le Bail, B
    Bioulac-Sage, P
    Rullier, E
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (05) : 602 - 606
  • [26] A novel preoperative protocol for locally advanced rectal cancer: Hyperfractionated short-course radiotherapy combined with chemotherapy
    Doi, Hiroshi
    Beppu, Naohito
    Takada, Yasuhiro
    Niwa, Yasue
    Fujiwara, Masayuki
    Kimura, Fumihiko
    Yanagi, Hidenori
    Yamanaka, Naoki
    Kamikonya, Norihiko
    Hirota, Shozo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [27] Peri-/postoperative quality control in locally advanced rectal cancer (LARC) after preoperative multimodal treatment (MMT) or upfront surgery - any evidence on survival?
    Grammatikopoulou, Tatiana
    Leha, Andreas
    Schanz, Julie
    Kreutzer, Johanna
    Werle, Laura
    de Boer, Charlotte
    Liersch, Torsten
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 77 - 78
  • [28] Is there any use in accelerated and hyperfractionated radiotherapy in locally advanced head and neck cancer?
    Monney, M
    Allal, A
    Guilleman, C
    Rosset, A
    Miralbell, R
    Kurtz, J
    Mirimanoff, RO
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 831 - 831
  • [29] HYPERFRACTIONATED, ACCELERATED RADIOTHERAPY AND CONCURRENT CHEMOTHERAPY IN LOCALLY ADVANCED BLADDER-CANCER
    JAKSE, G
    FRITSCH, E
    FROMMHOLD, H
    EUROPEAN UROLOGY, 1987, 13 (1-2) : 22 - 25
  • [30] Preoperative hyperfractionated radiotherapy for locally advanced rectal cancers:: A Phase I-II trial
    Allal, AS
    Bieri, S
    Bründler, MA
    Soravia, C
    Gertsch, P
    Bernier, J
    Morel, P
    Roth, AD
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2002, 54 (04): : 1076 - 1081